It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
Yes, the ACAM2000 is a live replicating vaccinia virus vaccine that, per the adverse reactions listed on the warnings insert, can cause severe disability, inflammation of the brain and spinal cord, permanent neurological sequelae (long term infection), death of the vaccinated individual, and … wait for it… “death of unvaccinated individuals who have contact with vaccinated individuals.” You cannot make this stuff up.
The CDC website on mpox vaccination states that ACAM2000 “has not been used in the ongoing clade II mpox outbreak that started in 2022″ but “has been made available for use against mpox in the clade II outbreak under an Expanded Access Investigational New Drug (EA-IND) protocol, which requires informed consent along with completing additional forms.”
The guide — which the FDA requires to be given to patients before they get the ACAM2000 vaccine — says, “ACAM2000 can cause serious complications in vaccinated individuals and in their close contacts to whom the vaccine virus has spread.”
Karl Jablonowski, Ph.D. — senior research scientist at Children’s Health Defense — told The Defender that the FDA’s approval of the shot is a “public hazard, not the practice of public health.”
“You can call ACAM2000 a ‘vaccine,’ but its impact on the United States will be as a ‘disease,’” Jablonowski said.
He added:
“For instance, the drug’s package insert reveals (see Table 3) that the U.S. Department of Health and Human Services (HHS) found roughly 520 per million ACAM2000 recipients contracted myocarditis or pericarditis.
“That is about 1 in 2,000. But elsewhere in the package insert, the FDA acknowledges that — based on additional studies — the risk is actually 5.7 per 1,000 vaccinations.
“That’s about 1 in every 175 people. If the 262 million adults in the U.S. received this vaccine, an estimated 1,493,000 would contract the serious adverse reaction of myopericarditis.”
Dr. Meryl Nass, an internist and biological warfare expert, told The Defender that the CDC also acknowledged this same figure — myopericarditis in 5.7 per 1,000 primary ACAM2000 vaccinations — during a June 23, 2022, meeting.
“It’s a huge number,” Nass said. “The fact that the FDA and CDC are acknowledging it means no one should get the vaccine.”
She explained:
“Myopericarditis is a life-threatening condition. It lowers your life expectancy.
“For instance, the drug’s package insert reveals (see Table 3) that the U.S. Department of Health and Human Services (HHS) found roughly 520 per million ACAM2000 recipients contracted myocarditis or pericarditis.
“That is about 1 in 2,000. But elsewhere in the package insert, the FDA acknowledges that — based on additional studies — the risk is actually 5.7 per 1,000 vaccinations.
“That’s about 1 in every 175 people. If the 262 million adults in the U.S. received this vaccine, an estimated 1,493,000 would contract the serious adverse reaction of myopericarditis.”
“Myopericarditis is a life-threatening condition. It lowers your life expectancy.
“Most people are never going to be exposed to mpox or smallpox. Vaccines are typically given to healthy people who are never even going to be exposed, therefore the risk posed by the vaccine needs to be low.
“That’s why vaccine safety is critical — even more than drugs, because drugs are given to people who are already sick.
“This risk — 1 in 175 — is higher than all other licensed vaccines for which the CDC acknowledges side effects. This is the worst.”
originally posted by: Boomer1947
a reply to: tarantulabite1
So, 1 in a million chance of dying from a Vacinnia infection (either naturally occurring or from the vaccine) compared to a 1 in 10 chance of dying from a Mpox infection if you haven't been vaccinated.
You decide.
Although many reports state that 10% of clade I infections in humans are fatal, infectious-disease researcher Laurens Liesenborghs at the Institute of Tropical Medicine in Antwerp, Belgium, doubts that this figure is accurate. Even the WHO’s latest estimate of a 3.5% fatality rate for people with mpox in the DRC might be high.
There are many reasons that fatality estimates might be unreliable, Liesenborghs says. For one, surveillance data capture only the most severe cases; many people who are less ill might not seek care at hospitals or through physicians, so their infections go unreported.
Another factor that can confound fatality rates is a secondary health condition. For example, people living with HIV — who can represent a large proportion of the population in many African countries — die from mpox at twice the rate of the general population2, especially if their HIV is untreated. And the relatively high death rate among children under age 5 could be partly because of malnutrition, which is common among kids in rural parts of the DRC, Liesenborghs says.
Up to 22 June 2022, 508 confirmed cases of monkeypox (MPX) have been reported in the Madrid region of Spain, 99% are men (n = 503) with a median age of 35 years (range: 18–67). In this ongoing outbreak, 427 cases (84.1%) reported condomless sex or sex with multiple partners within the 21 days before onset of symptoms, who were predominantly men who have sex with men (MSM) (n = 397; 93%). Both the location of the rash, mainly in the anogenital and perineal area, as well as the presence of inguinal lymphadenopathy suggest that close physical contact during sexual activity played a key role in transmission.
Get the vaccine if you:
Are a gay, bisexual, or other same-gender loving man who has sex with men or are transgender, gender non-binary, or gender-diverse AND in the last 6 months you have had, or expect to have
One or more sexually transmitted infections
More than one sexual partner, or anonymous sexual or intimate contact
Sex at a commercial sex venue
Sex in association with a large public event in a geographic area where mpox transmission is occurring
originally posted by: McGinty
Can the vaccine itself mutate in the recipient before being passed onto to others?
If so then this is an even worse idea than it already appeared to be at first glance.